Metraipolis › archive › dc_10aa653238df

Cost-effectiveness analysis of mepolizumab among patients with severe asthma from the Chinese societal perspective — Europe PMC PMID:42127033

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42127033
DOI: 10.1371/journal.pone.0348955
License (as archived): solo-consultazione
Archived: 2026-10-07T13:03:59.121Z
SHA-256 of the archived text: 3f1da5998779eec949f89e4b8e3d2a295379112728b57d2e2b97ed9716131998
Stable URL of this page: https://metraipolis.com/documento/dc_10aa653238df

How to cite

Cost-effectiveness analysis of mepolizumab among patients with severe asthma from the Chinese societal perspective — Europe PMC PMID:42127033 — Europe PMC (en), https://europepmc.org/article/MED/42127033 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_10aa653238df (Metraipolis archive dc_10aa653238df, sha256 3f1da5998779eec949f89e4b8e3d2a295379112728b57d2e2b97ed9716131998)

BibTeX

@misc{dc10aa653238df,
  title = {Cost-effectiveness analysis of mepolizumab among patients with severe asthma from the Chinese societal perspective — Europe PMC PMID:42127033},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42127033},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_10aa653238df; sha256 3f1da5998779eec949f89e4b8e3d2a295379112728b57d2e2b97ed9716131998},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42127033. Agents can read the archived copy with the MCP tool read_document.